Centene vs ResMed

Centene (CNC), health care, and ResMed (RMD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Centene is worth $35.9B on the stock market and ResMed $33.5B: Centene is valued at 7% more. Centene trades at 24.9 times earnings and ResMed at 21.7; operating margins in their latest fiscal years were -3.91% and 33.4%. Over the past year Centene's share price has moved +102% and ResMed's -3.26%.

Key facts

Centene market value
$35.9B
ResMed market value
$33.5B
Centene P/E
24.9
ResMed P/E
21.7
Centene revenue
$194.8BFY to 2025-12-31
ResMed revenue
$5.7BFY to 2026-06-30
Superinvestors holding both
0

Market values as of .

Centene vs ResMed: every measure side by side
Measure Centene ResMed
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312026-06-30
Size
Market cap$35.9Bhigher$33.5Blower
Revenue$194.8Bhigher$5.7Blower
Earnings-$6.7Blower$1.5Bhigher
Employees61,100higher11,370lower
Total assets$76.7Bhigher$9Blower
Valuation
P/E24.9higher21.7lower
P/S0.2lower5.9higher
P/B1.6lower5.6higher
Dividend yield0.00%lower1.03%higher
Profitability
Operating margin-3.91%lower33.4%higher
Balance sheet
Net assets$20Bhigher$6.6Blower
Total liabilities$56.7Bhigher$2.4Blower
Total debt$17.5Bhigher$659.4Mlower
Cash on hand$17.9Bhigher$1.5Blower
Price change
Today-2.97%lower-0.14%higher
1 year+102%higher-3.26%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns CNC · Who owns RMD

Further comparisons

Learn

Questions and answers

Which is bigger, Centene or ResMed?

By market value, Centene is the larger: $35.9B against $33.5B for ResMed. By revenue in its latest fiscal year, Centene is the larger: $194.8B against $5.7B for ResMed.

Which has the higher P/E ratio?

Centene: 24.9, against 21.7 for ResMed. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

ResMed: 33.4%, against -3.91% for Centene. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

ResMed: 1.03%, against 0.00% for Centene. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Centene: $17.5B, against $659.4M for ResMed. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Centene and ResMed?

None of the tracked superinvestors holds both in their latest 13F filing. 11 hold Centene and 1 holds ResMed.

Cite this page

Funkfolio, “Centene vs ResMed”, data as of 17 November 2026. https://funkfolio.com/compare/cnc-vs-rmd

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.